$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of bluebird bio, Inc. - BLUE
NEW YORK, Feb. 21, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating bluebird bio, Inc. (Nasdaq: BLUE), relating to the proposed merger with Beacon Parent Holdings, L.P. Under the terms of the agreement, bluebird stockholders will receive $3.00 per share and a contingent value right per share of $6.84 in cash if bluebird's current product portfolio achieves $600 million in net sales in a 12-month period before December 31, 2027.
Click here for more https://monteverdelaw.com/case/bluebird-bio-inc-blue/. It is free and there is no cost or obligation to you.
NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask:
About Monteverde & Associates PC
Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.
No company, director or officer is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.
Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341
Attorney Advertising. (C) 2024 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
View original content to download multimedia:https://www.prnewswire.com/news-releases/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-bluebird-bio-inc--blue-302382464.html
SOURCE Monteverde & Associates PC
Übrigens: US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Nachrichten zu bluebird bio Inc
Analysen zu bluebird bio Inc
Datum | Rating | Analyst | |
---|---|---|---|
18.06.2019 | bluebird bio Buy | Maxim Group | |
22.02.2019 | bluebird bio Neutral | Cantor Fitzgerald | |
02.11.2018 | bluebird bio Neutral | Cantor Fitzgerald | |
12.07.2018 | bluebird bio Buy | Gabelli & Co | |
22.02.2018 | bluebird bio Underweight | Cantor Fitzgerald |
Datum | Rating | Analyst | |
---|---|---|---|
18.06.2019 | bluebird bio Buy | Maxim Group | |
12.07.2018 | bluebird bio Buy | Gabelli & Co | |
13.12.2017 | bluebird bio Overweight | Barclays Capital | |
05.12.2017 | bluebird bio Buy | Canaccord Adams | |
30.11.2017 | bluebird bio Buy | Maxim Group |
Datum | Rating | Analyst | |
---|---|---|---|
22.02.2019 | bluebird bio Neutral | Cantor Fitzgerald | |
02.11.2018 | bluebird bio Neutral | Cantor Fitzgerald | |
21.12.2017 | bluebird bio Perform | Oppenheimer & Co. Inc. | |
13.12.2017 | bluebird bio Hold | Maxim Group | |
30.06.2017 | bluebird bio Neutral | BTIG Research |
Datum | Rating | Analyst | |
---|---|---|---|
22.02.2018 | bluebird bio Underweight | Cantor Fitzgerald | |
11.12.2017 | bluebird bio Underweight | Cantor Fitzgerald | |
16.06.2017 | bluebird bio Reduce | Standpoint Research | |
14.10.2016 | bluebird bio Sell | Cantor Fitzgerald |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für bluebird bio Inc nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen